|
|
 |
|
Viewing report
|
|
|
|
Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application - 2 Volume Set
John Wiley and Sons Ltd, March 2007, Pages: 1,260
Antidepressants and related psychiatric drugs are the most important prescription drugs worldwide, accounting for a market volume of 20 billion US$ per year. This handbook provides a complete and detailed overview of all currently available psychiatric drugs, covering more than 250 different compounds.
Particular features include:
- the most important information on the chemistry, pharmacology and therapeutic use of a given drug
- a special layout with margin notes and compound structures allowing for quick and easy access to the desired information
Written by drug developers from the pharmaceutical industry, novel drugs currently under development and new methods of treatment are listed side by side with classical drugs, allowing a direct comparison of traditional and innovative therapeutic approaches.
Author information
The editors all work for the Spanish-based pharmaceutical company Esteve, a world leader in neuropharmaceuticals.
Helmut Buschmann is the research director of Esteve, in charge of the discovery and development of new active substances for a variety of neurological disorders. He was formerly the head of research at Gruenenthal, a Germany-based pharma company that also specialized in neuropharmaceuticals. During his time at Gruenenthal, he published a widely acclaimed book on analgesics that pioneered the integrated approach followed also in his most recent book.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Principles of CNS Drug Development: From Test Tube to Patient
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules
Schizophrenia, 3rd Edition
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
Anxiety Disorders - Global Strategic Business Report
Seroquel - Analysis and Estimates from 2002 to 2020
Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Cariprazine - Analysis and Forecasts from 2013 to 2020
Saphris - Analysis and Estimates from 2009 to 2020
Latuda - Analysis and Forecasts from 2011 to 2020
|
|
|
|
